MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525276 | Name: nor-Binaltorphimine dihydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

nor-Binaltorphimine dihydrochloride is a long-acting potent and highly selective kappa opioid receptor antagonist.

Chemical Structure

nor-Binaltorphimine dihydrochloride
nor-Binaltorphimine dihydrochloride
CAS#105618-26-6

Theoretical Analysis

MedKoo Cat#: 525276

Name: nor-Binaltorphimine dihydrochloride

CAS#: 105618-26-6

Chemical Formula: C40H45Cl2N3O6

Exact Mass: 733.2685

Molecular Weight: 734.72

Elemental Analysis: C, 65.39; H, 6.17; Cl, 9.65; N, 5.72; O, 13.07

Price and Availability

Size Price Availability Quantity
10mg USD 385.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
nor-Binaltorphimine dihydrochloride
IUPAC/Chemical Name
17,17-Bis(cyclopropylmethyl)-6,6,7,7-tetradehydro-4,5,4,5-diepoxy-6,6-(imino)[7,7-bimorphinan]-3,3,14,14-tetrol
InChi Key
KRXZMLKMDYBRCK-YAUKWVCOSA-N
InChi Code
InChI=1S/C40H45Cl2N3O6/c46-25-7-5-21-13-27-39(48)15-23-24-16-40(49)28-14-22-6-8-26(47)34-30(22)38(40,10-12-42-45(28)18-20-3-4-20)36(51-34)32(24)43-31(23)35-37(39,29(21)33(25)50-35)9-11-41-44(27)17-19-1-2-19/h5-8,19-20,27-28,35-36,41-43,46-49H,1-4,9-18H2/t27-,28-,35+,36+,37+,38+,39-,40-/m1/s1
SMILES Code
O[C@@]12CC3=C(NC4=C3C[C@]5(O)[C@]67[C@H]4OC8=C(O)C=CC(C[C@H]5N(CC9CC9)[ClH]CC7)=C68)[C@H]%10[C@]1%11C%12=C(C=CC(O)=C%12O%10)C[C@H]2N(CC%13CC%13)[ClH]CC%11
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
nor-Binaltorphimine dihydrochloride is a long-acting potent and highly selective kappa opioid receptor antagonist.
In vitro activity:
The opioid antagonist activities of two bivalent ligands, BNI and nor-BNI, have been evaluated in smooth muscle preparations and in mice. Both ligands are highly potent and selective as kappa opioid receptor antagonists, with relatively feeble blocking activity at mu and delta opioid receptors. Reference: Life Sci. 1987 Mar 30;40(13):1287-92. https://pubmed.ncbi.nlm.nih.gov/2882399/
In vivo activity:
Rats were then administered norBNI (binaltorphimine) (0, 0.02, 0.08, or 0.32 μmol) followed by morphine (0 or 0.32 μmol). Nociception was reassessed 30 min after drug treatment, and recovery was evaluated for 21 days. The effects of norBNI on morphine-induced attenuation of recovery were dose dependent. At higher doses, norBNI blocked the adverse effects of morphine on locomotor recovery, but analgesia was also significantly decreased. Reference: J Neurotrauma. 2017 Mar 15;34(6):1164-1174. https://pubmed.ncbi.nlm.nih.gov/27736318/

Preparing Stock Solutions

The following data is based on the product molecular weight 734.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987 Mar 30;40(13):1287-92. doi: 10.1016/0024-3205(87)90585-6. PMID: 2882399. 2. Aceves M, Bancroft EA, Aceves AR, Hook MA. Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury. J Neurotrauma. 2017 Mar 15;34(6):1164-1174. doi: 10.1089/neu.2016.4601. Epub 2016 Nov 4. PMID: 27736318; PMCID: PMC5359644. 3. Kelsey JE, Verhaak AM, Schierberl KC. The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats. Behav Brain Res. 2015 Apr 15;283:16-21. doi: 10.1016/j.bbr.2015.01.008. Epub 2015 Jan 13. PMID: 25591478.
In vitro protocol:
1. Portoghese PS, Lipkowski AW, Takemori AE. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987 Mar 30;40(13):1287-92. doi: 10.1016/0024-3205(87)90585-6. PMID: 2882399.
In vivo protocol:
1. Aceves M, Bancroft EA, Aceves AR, Hook MA. Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury. J Neurotrauma. 2017 Mar 15;34(6):1164-1174. doi: 10.1089/neu.2016.4601. Epub 2016 Nov 4. PMID: 27736318; PMCID: PMC5359644. 2. Kelsey JE, Verhaak AM, Schierberl KC. The kappa-opioid receptor antagonist, nor-binaltorphimine (nor-BNI), decreases morphine withdrawal and the consequent conditioned place aversion in rats. Behav Brain Res. 2015 Apr 15;283:16-21. doi: 10.1016/j.bbr.2015.01.008. Epub 2015 Jan 13. PMID: 25591478.
1: Cristina-Silva C, Martins V, Gargaglioni LH, Bícego KC. Mu and kappa opioid receptors of the periaqueductal gray stimulate and inhibit thermogenesis, respectively, during psychological stress in rats. Pflugers Arch. 2017 Apr 4. doi: 10.1007/s00424-017-1966-2. [Epub ahead of print] PubMed PMID: 28374069. 2: Maraschin JC, Almeida CB, Rangel MP, Roncon CM, Sestile CC, Zangrossi H Jr, Graeff FG, Audi EA. Participation of dorsal periaqueductal gray 5-HT1A receptors in the panicolytic-like effect of the κ-opioid receptor antagonist Nor-BNI. Behav Brain Res. 2017 Jun 1;327:75-82. doi: 10.1016/j.bbr.2017.03.033. Epub 2017 Mar 24. PubMed PMID: 28347824. 3: Yeganeh-Hajahmadi M, Najafipour H, Rostamzadeh F. The differential effects of low and high doses of apelin through opioid receptors on the blood pressure of rats with renovascular hypertension. Hypertens Res. 2017 Mar 9. doi: 10.1038/hr.2017.28. [Epub ahead of print] PubMed PMID: 28275232. 4: Kim HJ, Kim H, Jung MH, Kwon YK, Kim BJ. Berberine induces pacemaker potential inhibition via cGMP-dependent ATP-sensitive K+ channels by stimulating mu/delta opioid receptors in cultured interstitial cells of Cajal from mouse small intestine. Mol Med Rep. 2016 Oct;14(4):3985-91. doi: 10.3892/mmr.2016.5698. Epub 2016 Sep 1. PubMed PMID: 27601272. 5: Whitfield TW Jr, Schlosburg JE, Wee S, Gould A, George O, Grant Y, Zamora-Martinez ER, Edwards S, Crawford E, Vendruscolo LF, Koob GF. κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J Neurosci. 2015 Mar 11;35(10):4296-305. doi: 10.1523/JNEUROSCI.1978-13.2015. PubMed PMID: 25762676; PubMed Central PMCID: PMC4355200. 6: Funk D, Coen K, Lê AD. The role of kappa opioid receptors in stress-induced reinstatement of alcohol seeking in rats. Brain Behav. 2014 May;4(3):356-67. doi: 10.1002/brb3.222. Epub 2014 Feb 17. PubMed PMID: 24944865; PubMed Central PMCID: PMC4055186. 7: Lv SY, Qin YJ, Wang HT, Xu N, Yang YJ, Chen Q. Centrally administered apelin-13 induces depression-like behavior in mice. Brain Res Bull. 2012 Sep 1;88(6):574-80. doi: 10.1016/j.brainresbull.2012.06.003. Epub 2012 Jun 21. PubMed PMID: 22728209. 8: Ruisanchez É, Cselenyák A, Papp RS, Németh T, Káldi K, Sándor P, Benyó Z. Perivascular expression and potent vasoconstrictor effect of dynorphin A in cerebral arteries. PLoS One. 2012;7(5):e37798. doi: 10.1371/journal.pone.0037798. Epub 2012 May 25. PubMed PMID: 22662226; PubMed Central PMCID: PMC3360594. 9: Chicre-Alcântara TC, Torres-Chávez KE, Fischer L, Clemente-Napimoga JT, Melo V, Parada CA, Tambeli CH. Local kappa opioid receptor activation decreases temporomandibular joint inflammation. Inflammation. 2012 Feb;35(1):371-6. doi: 10.1007/s10753-011-9329-1. PubMed PMID: 21484425. 10: Cole S, Richardson R, McNally GP. Kappa opioid receptors mediate where fear is expressed following extinction training. Learn Mem. 2011 Jan 18;18(2):88-95. doi: 10.1101/lm.2049511. Print 2011 Feb. PubMed PMID: 21245209. 11: Wiskerke J, Schetters D, van Es IE, van Mourik Y, den Hollander BR, Schoffelmeer AN, Pattij T. μ-Opioid receptors in the nucleus accumbens shell region mediate the effects of amphetamine on inhibitory control but not impulsive choice. J Neurosci. 2011 Jan 5;31(1):262-72. doi: 10.1523/JNEUROSCI.4794-10.2011. PubMed PMID: 21209211. 12: Beardsley PM, Pollard GT, Howard JL, Carroll FI. Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl ]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. Psychopharmacology (Berl). 2010 Jun;210(2):189-98. doi: 10.1007/s00213-010-1846-3. Epub 2010 Apr 7. PubMed PMID: 20372878; PubMed Central PMCID: PMC2872796. 13: Scarpellini Cda S, Gargaglioni LH, Branco LG, Bícego KC. Role of preoptic opioid receptors in the body temperature reduction during hypoxia. Brain Res. 2009 Aug 25;1286:66-74. doi: 10.1016/j.brainres.2009.06.039. Epub 2009 Jun 21. PubMed PMID: 19545549. 14: Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res. 2008 Oct;33(10):2142-50. doi: 10.1007/s11064-008-9752-3. Epub 2008 Jun 5. PubMed PMID: 18528756; PubMed Central PMCID: PMC2574661. 15: Frithiof R, Eriksson S, Rundgren M. Central inhibition of opioid receptor subtypes and its effect on haemorrhagic hypotension in conscious sheep. Acta Physiol (Oxf). 2007 Sep;191(1):25-34. Epub 2007 Jun 5. PubMed PMID: 17550406. 16: Rutz S, Riegert C, Rothmaier AK, Jackisch R. Presynaptic modulation of 5-HT release in the rat septal region. Neuroscience. 2007 May 11;146(2):643-58. Epub 2007 Mar 23. PubMed PMID: 17383104. 17: Gaumond I, Spooner MF, Marchand S. Sex differences in opioid-mediated pain inhibitory mechanisms during the interphase in the formalin test. Neuroscience. 2007 Apr 25;146(1):366-74. Epub 2007 Feb 15. PubMed PMID: 17306464. 18: Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem. 2004 Sep;90(5):1258-68. PubMed PMID: 15312181. 19: Yokoyama O, Mita E, Akino H, Tanase K, Ishida H, Namiki M. Roles of opiate in lower urinary tract dysfunction associated with spinal cord injury in rats. J Urol. 2004 Feb;171(2 Pt 1):963-7. PubMed PMID: 14713862. 20: Zhang Z, Chen TY, Kirsch JR, Toung TJ, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A. Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg. 2003 Dec;97(6):1776-83. PubMed PMID: 14633559.